BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34933726)

  • 1. Serum  JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients.
    Petrusel L; Ilies M; Leucuta D; Rusu I; Seicean A; Iuga C; Seicean R
    Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):107-112. PubMed ID: 34933726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.
    Denley SM; Jamieson NB; McCall P; Oien KA; Morton JP; Carter CR; Edwards J; McKay CJ
    J Gastrointest Surg; 2013 May; 17(5):887-98. PubMed ID: 23435739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Song Y; Tang MY; Chen W; Wang Z; Wang SL
    Dis Markers; 2020; 2020():7656031. PubMed ID: 33029256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.
    Yako YY; Brand M; Smith M; Kruger D
    Pancreatology; 2017; 17(3):438-444. PubMed ID: 28377069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
    Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
    Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin expression and serum levels in pancreatic cancer.
    Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
    World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
    Yako YY; Kruger D; Smith M; Brand M
    PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
    Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
    Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
    Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
    BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma.
    Ren YQ; Zhang HY; Su T; Wang XH; Zhang L
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3063-8. PubMed ID: 25392106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
    Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
    Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer.
    Felix K; Hinz U; Dobiasch S; Hackert T; Bergmann F; Neumüller M; Gronowitz S; Bergqvist M; Strobel O
    Pancreas; 2018 Jan; 47(1):72-79. PubMed ID: 29189449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin involvement in the survival of pancreatic adenocarcinoma patients with obesity and diabetes.
    Man T; Seicean R; Lucaciu L; Leucuta D; Ilies M; Iuga C; Petrusel L; Seicean A
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1341-1349. PubMed ID: 35253190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.